Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)

  • Technology appraisal
  • TA436
  • Published: 

History

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

Draft scope documents